at bionano genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. our team is not afraid to venture into uncharted territory to look for answers. we welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home. our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what’s missing from sequencing-based data. saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities and the ability to construct the most complete genome assemblies. at bionano, we are invested in the success of our customers and users around the world, and are dedicated to supporting them with the tools, resources and support they need to achieve their goals and make a real impact on improving quality o
Company profile
Ticker
BNGO
Exchange
Website
CEO
R. Erik Holmlin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BioNano Genomics, Inc, Bionano Genomics, Inc, BioNanomatrix Inc
SEC CIK
Corporate docs
Subsidiaries
Bionano Genomics UK, Ltd. • Bionano Genomics (Shanghai) Trading Co., Ltd. • BioDiscovery, Inc • Lineagen, Inc. • Purigen Biosystems, Inc. • PURIGEN BIOSYSTEMS UK LTD ...
BNGO stock data
Latest filings (excl ownership)
8-K
Bionano Announces Private Placement of Senior Secured Notes in Debt Restructuring that Improves Balance Sheet
28 May 24
S-8
Registration of securities for employees
8 May 24
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
Bionano Reports First Quarter 2024 Results and Highlights Recent Business Progress
8 May 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Other Events
8 Apr 24
424B5
Prospectus supplement for primary offering
8 Apr 24
8-K
Bionano Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
5 Apr 24
ARS
2023 FY
Annual report to shareholders
6 Mar 24
Transcripts
BNGO
Earnings call transcript
2024 Q1
8 May 24
BNGO
Earnings call transcript
2023 Q4
5 Mar 24
BNGO
Earnings call transcript
2023 Q3
8 Nov 23
BNGO
Earnings call transcript
2023 Q2
9 Aug 23
BNGO
Earnings call transcript
2023 Q2
9 Aug 23
BNGO
Earnings call transcript
2023 Q1
9 May 23
BNGO
Earnings call transcript
2022 Q4
9 Mar 23
BNGO
Earnings call transcript
2022 Q3
4 Nov 22
BNGO
Earnings call transcript
2022 Q2
5 Aug 22
BNGO
Earnings call transcript
2022 Q1
6 May 22
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 16.16 mm | 16.16 mm | 16.16 mm | 16.16 mm | 16.16 mm | 16.16 mm |
Cash burn (monthly) | 729.67 k | (no burn) | 10.48 mm | 18.98 mm | 9.38 mm | 10.07 mm |
Cash used (since last report) | 1.51 mm | n/a | 21.69 mm | 39.30 mm | 19.41 mm | 20.86 mm |
Cash remaining | 14.65 mm | n/a | -5.53 mm | -23.14 mm | -3.25 mm | -4.70 mm |
Runway (months of cash) | 20.1 | n/a | -0.5 | -1.2 | -0.3 | -0.5 |
Institutional ownership, Q4 2023
0.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 1 |
Closed positions | 48 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 131.67 mm |
Total shares | 69.68 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Archford Capital Strategies | 69.56 k | $131.48 mm |
FITB Fifth Third Bancorp | 71.00 | $134.00 k |
Compagnie Lombard Odier SCmA | 20.00 | $38.00 k |
AdvisorNet Financial | 10.00 | $19.00 k |
Householder Group Estate & Retirement Specialist | 10.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Feb 24 | Alka Chaubey | Common Stock | Payment of exercise | Dispose F | No | No | 1.27 | 1,081 | 1.37 k | 31,487 |
15 Feb 24 | Mark Oldakowski | Common Stock | Payment of exercise | Dispose F | No | No | 1.27 | 1,229 | 1.56 k | 48,644 |
15 Feb 24 | Jonathan V. Dixon | Common Stock | Payment of exercise | Dispose F | No | No | 1.27 | 402 | 510.54 | 3,525 |
15 Feb 24 | R. Erik Holmlin | Common Stock | Payment of exercise | Dispose F | No | No | 1.27 | 3,073 | 3.90 k | 77,663 |
18 Sep 23 | Gulsen Kama | Stock Option Common Stock | Grant | Acquire A | No | No | 3 | 106,000 | 318.00 k | 106,000 |
News
Bionano Receives $18M In Private Placement Of Senior Secured Notes In Debt Restructuring That Improves Balance Sheet
28 May 24
Three Publications Demonstrate Bionano's OGM's Utility For Cell And Gene Therapy; Publications Include Niño Jesús University Children's Hospital; Ruhr-University Bochum And Janssen
21 May 24
BTIG Maintains Buy on Bionano Genomics, Lowers Price Target to $2
16 May 24
Bionano Genomics Q1 2024 GAAP EPS $(0.60) Beats $(0.65) Estimate, Sales $8.769M Beat $8.492M Estimate
8 May 24
Bionano Announces Publication Showing OGM's High Resolution Structural Variation Detection In Cancer Validated By Cas9-Directed Nanopore Sequencing
24 Apr 24
Press releases
Bionano Announces Robust Presence at Upcoming Cytogenetics Conferences ESHG and ACC with 39 Scientific Presentations and Posters Highlighting the Utility of the Optical Genome Mapping Workflow
30 May 24
Bionano Reports First Quarter 2024 Results and Highlights Recent Business Progress
8 May 24
Bionano to Report First Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 8, 2024
1 May 24
Bionano Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4 Apr 24
Bionano Reports Fourth Quarter and Full-Year 2023 Results and Provides Revenue Outlook for 2024
5 Mar 24